BioSpace News Archive

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, is scheduled to present at the virtual Bank of America Securities 2020 Health Care Conference on Thursday, May 14, 2020, at 11:40 a.m. ET. A live webcast of the fireside chat will be avail

FogPharma today announced the appointment of Tony Gibney as Chief Financial Officer and Chief Business Officer.

Lipocine Inc., a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced financial results for the first quarter ended March 31, 2020, and provided a corporate update.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, annou

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, reported financial results for the first quarter ended March 31, 2020, and provided a business update.

In light of recent market rumors, TearLab Corporation confirmed that TearLab is engaged in advanced discussions regarding a potential business combination whereby TearLab will be acquired at a price per share equal to $0.0586.

Leading TMS Company honors clinicians on the front lines who remain dedicated to serving the country’s mental health needs, during May and beyond

Precision Optics Corporation, Inc. announced that it has scheduled a conference call to discuss third quarter of fiscal 2020 financial results on Thursday, May 14, 2020 at 5:00pm ET.

Commenced dosing of patients with solid tumors that exhibit primary resistance to anti-PD(L)1 therapy in the DRAGON Phase 1 clinical trial of SRK-181; update on dose escalation expected in 4Q20

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA to treat serious and life-threatening infections, today reported financial results for the first quarter ended March 31, 2020.